速递 | 增强NK细胞抗癌效力和持久性，新锐完成1.72亿美元B轮融资
▎药明康德内容团队编辑
参考资料：
[1] Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials. Retrieved July 15, 2021, from https://www.businesswire.com/news/home/20210715005109/en/Wugen-Raises-172-Million-to-Advance-Clinical-Stage-Memory-NK-Cell-Platform-Progress-Best-In-Class-AML-Program-and-Initiate-Multiple-Solid-Tumor-Trials
[2] New CEO, check. $172M round, check. Wugen's off-the-shelf cell therapies are ready for takeoff. Retrieved July 15, 2021, from https://www.fiercebiotech.com/biotech/new-ceo-check-172m-round-check-wugen-s-off-shelf-cell-therapies-are-ready-for-take-off
[3] A stealthy startup is leveraging natural killer cells with 'memory-like' abilities to go after blood cancer and beyond. Retrieved July 15, 2021, from https://endpts.com/a-stealthy-startup-is-leveraging-natural-killer-cells-with-memory-like-abilities-to-go-after-blood-cancer-and-beyond/
版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。